Synhumans for Peptech

Peptech has announced the implementation of a proprietary antibody based therapeutic technology platform, named "Synhumanisation", which promises to enable therapeutic drugs to be developed against multiple medical targets.

Synhumanisation is centred on the use of human-like antibody sequences in place of mouse sequences in order to avoid potentially harmful immune responses in humans. The Synhumanisation platform will result in increased discovery of patentable new antibody products, the company said.

"The platform represents a strategic milestone for the company and the commitment to deliver an in-house platform for the development of new antibody-based drug leads," Peptech CEO Dr John Chiplin said.

"The implementation of the Synhumanisation technology platform focuses on the development of potential products to bolster Peptech's existing pipeline.

"The successful application of this technology will add to Peptech's pipeline by enabling us to discover new products against additional (medical) targets, particularly those which have proven successful through human trials undertaken by other pharmaceutical and biotech companies.

"This technology was developed to provide Peptech with a competitive advantage by providing the means to access high value targets without being blocked by patents held by others. In other words it gives Peptech the freedom to develop drugs without falling under the scope of other companies' patents."

The technology is already being applied by Peptech to two validated, high value Targets, Chiplin said.

Source: Peptech